Participant characteristics (median values with IQR shown in parentheses, both strata combined)
| . | rhIL-7, n = 18 . | Placebo, n = 6 . |
|---|---|---|
| Race/ethnicity | ||
| White, not Hispanic | 12 | 5 |
| Black, not Hispanic | 4 | 1 |
| Hispanic, Latino | 2 | 0 |
| Age | 44 (41-48) | 48 (39-51) |
| Sex, male/female | 14/4 | 6/0 |
| CD4 T cells/μL | 540 (323-705) | 460 (242-781) |
| CD8 T cells/μL | 1031 (786-1222) | 795 (632-1209) |
| CD4/CD8 ratio | 0.47 (0.38-0.78) | 0.50 (0.23-1.18) |
| Nadir CD4 T cells/μL | ||
| < 50 | 6 | 4 |
| 51-100 | 2 | 0 |
| 101-200 | 6 | 1 |
| 201-500 | 2 | 1 |
| > 500 | 2 | 0 |
| HIV-RNA, copies/mL | < 50 (< 50-207) | < 50 (< 50-306) |
| HIV-RNA < 50 copies/mL | 12 | 4 |
| . | rhIL-7, n = 18 . | Placebo, n = 6 . |
|---|---|---|
| Race/ethnicity | ||
| White, not Hispanic | 12 | 5 |
| Black, not Hispanic | 4 | 1 |
| Hispanic, Latino | 2 | 0 |
| Age | 44 (41-48) | 48 (39-51) |
| Sex, male/female | 14/4 | 6/0 |
| CD4 T cells/μL | 540 (323-705) | 460 (242-781) |
| CD8 T cells/μL | 1031 (786-1222) | 795 (632-1209) |
| CD4/CD8 ratio | 0.47 (0.38-0.78) | 0.50 (0.23-1.18) |
| Nadir CD4 T cells/μL | ||
| < 50 | 6 | 4 |
| 51-100 | 2 | 0 |
| 101-200 | 6 | 1 |
| 201-500 | 2 | 1 |
| > 500 | 2 | 0 |
| HIV-RNA, copies/mL | < 50 (< 50-207) | < 50 (< 50-306) |
| HIV-RNA < 50 copies/mL | 12 | 4 |